Capan-2人胰腺癌细胞

 

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

 

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

 

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

 

PubMed=3019537
Kyriazis A.A., Kyriazis A.P., Sternberg C.N., Sloane N.H., Loveless J.D.
Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse.
Cancer Res. 46:5810-5815(1986)

 

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

 

PubMed=1764370; DOI=10.1038/bjc.1991.467
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)

 

PubMed=1630814
Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J.P.
Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Oncogene 7:1503-1511(1992)

 

PubMed=8426738
Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E., Maurer J., Maacke H., Deppert W.
p53 and K-RAS alterations in pancreatic epithelial cell lesions.
Oncogene 8:289-298(1993)

 

PubMed=7809022; DOI=10.1097/00006676-199409000-00018
Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
Pancreas 9:657-661(1994)

 

PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x
Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M.
K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.
Jpn. J. Cancer Res. 85:1005-1014(1994)

 

PubMed=7972006; DOI=10.1073/pnas.91.23.11045
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

 

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

 

PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7
Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G., Arnold R.
Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.
Gastroenterology 106:1645-1651(1994)

 

PubMed=8286197; DOI=10.1038/bjc.1994.24
Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.
Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.
Br. J. Cancer 69:144-151(1994)

 

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

 

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

 

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

 

PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)

 

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

 

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

 

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

 

PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159
Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Cancer Res. 64:3052-3059(2004)

 

PubMed=15367885; DOI=10.1097/00006676-200410000-00004
Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S.
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Pancreas 29:193-203(2004)

 

PubMed=15688027; DOI=10.1038/sj.onc.1208383
Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H., Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Oncogene 24:1794-1801(2005)

 

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

 

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x
Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J. Cell. Mol. Med. 12:2823-2835(2008)

 

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

 

 

CLPUB00416

Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany

 

 

DOI=10.4172/jpb.1000057
Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
J. Proteomics Bioinformatics 2:1-18(2009)

 

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

 

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

 

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

 

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

 

PubMed=24700732; DOI=10.1002/humu.22556
Leroy B., Girard L., Hollestelle A., Minna J.D., Gazdar A.F., Soussi T.
Analysis of TP53 mutation status in human cancer cell lines: a reassessment.
Hum. Mutat. 35:756-765(2014)